Tech Company Financing Transactions
Immunocore Funding Round
General Atlantic, Bill & Melinda Gates Foundation and CCB International participated in a $130 million Series B funding round for Immunocore. The round was announced on 3/3/2020.
Transaction Overview
Company Name
Announced On
3/3/2020
Transaction Type
Venture Equity
Amount
$130,000,000
Round
Series B
Investors
Proceeds Purpose
The proceeds will enable Immunocore to further expand and accelerate its rapidly growing clinical stage pipeline of ImmTAX molecules.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
181 Washington St. 6 Tower Bridge 200
Conshohocken, PA 19428
USA
Conshohocken, PA 19428
USA
Phone
Website
Email Address
Overview
We are a leading T cell receptor (TCR) biotechnology company, focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. Our most advanced therapeutic programmes are focused on oncology, and we also have programmes in infectious and autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bahija Jallal
Chief Medical Officer
Mohammed Dar
Chief Scientific Officer
Bent Jakobsen
VP - R & D
David Berman
Browse more venture capital transactions:
Prev: 3/3/2020: Xilio Therapeutics venture capital transaction
Next: 3/3/2020: Public.com venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs